Oculis Holding AG (NASDAQ:OCS - Get Free Report) shares rose 7.4% on Tuesday . The company traded as high as $15.57 and last traded at $15.44. Approximately 13,745 shares changed hands during trading, a decline of 71% from the average daily volume of 46,844 shares. The stock had previously closed at $14.37.
Analysts Set New Price Targets
OCS has been the topic of several research analyst reports. Robert W. Baird boosted their price target on shares of Oculis from $37.00 to $41.00 and gave the company an "outperform" rating in a research report on Thursday, March 13th. Chardan Capital reissued a "buy" rating and issued a $28.00 target price on shares of Oculis in a research report on Thursday, March 13th. Finally, HC Wainwright lowered their target price on Oculis from $30.00 to $29.00 and set a "buy" rating for the company in a research note on Thursday, March 13th.
Get Our Latest Analysis on Oculis
Oculis Price Performance
The firm has a market cap of $731.34 million, a P/E ratio of -8.68 and a beta of 0.19. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.02 and a quick ratio of 4.02. The firm's 50 day moving average is $19.22 and its 200 day moving average is $17.82.
Oculis (NASDAQ:OCS - Get Free Report) last issued its quarterly earnings results on Tuesday, March 11th. The company reported ($0.76) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.28). Oculis had a negative return on equity of 71.31% and a negative net margin of 8,043.28%. As a group, analysts anticipate that Oculis Holding AG will post -2.09 earnings per share for the current year.
Hedge Funds Weigh In On Oculis
Institutional investors and hedge funds have recently modified their holdings of the stock. Bellevue Group AG bought a new position in Oculis in the 4th quarter worth about $170,000. XTX Topco Ltd bought a new position in shares of Oculis in the fourth quarter worth approximately $225,000. Geode Capital Management LLC lifted its stake in shares of Oculis by 12.0% in the fourth quarter. Geode Capital Management LLC now owns 16,744 shares of the company's stock worth $284,000 after buying an additional 1,800 shares in the last quarter. Citadel Advisors LLC purchased a new stake in shares of Oculis during the fourth quarter valued at approximately $389,000. Finally, Bank of America Corp DE increased its position in shares of Oculis by 58.2% during the fourth quarter. Bank of America Corp DE now owns 28,980 shares of the company's stock valued at $493,000 after acquiring an additional 10,667 shares in the last quarter. 22.30% of the stock is currently owned by institutional investors.
About Oculis
(
Get Free Report)
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
Recommended Stories
Before you consider Oculis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oculis wasn't on the list.
While Oculis currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
